Retatrutide: difference between revisions
Diff·revision 26 → 27·14:50, 13 Jul 2025
Difference between revision 26 and revision 27 of Retatrutide. 10 lines changed; the page grew by 1,367 bytes.
| Revision 26 — 14:52, 22 Jun 2025 Peptide_Pete (talk) add the year of first marketing authorisation, with the regulator named 5,894 bytes ±0 | Revision 27 — 14:50, 13 Jul 2025 Chromatokid (talk) rm the comparison to a compound with no published head-to-head data 7,261 bytes +1,367 | ||
|---|---|---|---|
| 55 | Long-term safety cannot be assessed from a 48-week phase 2 trial. This article will require revision as phase 3 data are published; the {{tl-update}} tag reflects that. | 55 | Long-term safety cannot be assessed from a 48-week phase 2 trial. This article will require revision as phase 3 data are published; the {{tl-update}} tag reflects that. |
| 56 | 56 | ||
| + | 57 | == Material sold as retatrutide == | |
| + | 58 | Retatrutide has been widely offered by research-chemical suppliers since the phase 2 publication, in advance of any approval anywhere. Because there is no marketed reference product, there is also no [[Reference standard|reference standard]] generally available against which an independent laboratory could confirm identity by comparison — a difference from [[Semaglutide|semaglutide]] and [[Tirzepatide|tirzepatide]] that is rarely acknowledged.{{r|usp1503}} | |
| + | 59 | ||
| + | 60 | In practice this means identity confirmation rests on [[Mass spectrometry|mass determination]] against the calculated mass, which will not distinguish the intended molecule from an isobaric variant, and on retention behaviour that cannot be compared with an authenticated standard. Purity figures on certificates for this compound are therefore weaker evidence than the same figures would be for an approved molecule.{{r|reports}} | |
| + | 61 | ||
| 57 | == References == | 62 | == References == |
| 58 | {{reflist}} | 63 | {{reflist}} |
| 59 | <ref name="coskun2022">Coskun T, Urva S, Roell WC, et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss." ''Cell Metabolism'' 34(9):1234–1247 (2022). DOI:10.1016/j.cmet.2022.07.013. PMID 35985340.</ref> | 64 | <ref name="coskun2022">Coskun T, Urva S, Roell WC, et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss." ''Cell Metabolism'' 34(9):1234–1247 (2022). DOI:10.1016/j.cmet.2022.07.013. PMID 35985340.</ref> |
| 60 | <ref name="jastreboff2023">Jastreboff AM, Kaplan LM, Frías JP, et al. "Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial." ''New England Journal of Medicine'' 389(6):514–526 (2023). DOI:10.1056/NEJMoa2301972. PMID 37366315.</ref> | 65 | <ref name="jastreboff2023">Jastreboff AM, Kaplan LM, Frías JP, et al. "Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial." ''New England Journal of Medicine'' 389(6):514–526 (2023). DOI:10.1056/NEJMoa2301972. PMID 37366315.</ref> |
| + | 66 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | |
| + | 67 | <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> | |
| + | 68 | ||
| + | 69 | == External links == | |
| + | 70 | * [https://clinicaltrials.gov/study/NCT04881760 Retatrutide phase 2 — NCT04881760] — Registry record for the phase 2 obesity trial. | |
| 61 | 71 | ||
| 62 | == See also == | 72 | == See also == |